## **FDA EUA for ReEBOV Rapid Test for Ebola NIAID** award **NIAID** award **Launch of Pan Preclinical evaluation Antibody Immuno-**WHO EUAL of LASV GP/NP of LF immunotherapeutics for **ReEBOV Rapid** IgM/IgG ELISA therapeutic biodefense against **Test for Ebola** product line **LASV NIAID** award **CEPI** award **Launch of Ebola NIAID** award **Structure based CEPI ENABLE Arevirumab-3** diagnostic Launch of IVD. design of novel Structure-guided **NIAID** award pre-IND products in West **RUO SARS CoV-2** Serology Zalgen History reviewed by **Africa Ebola LASV GP for vaccine Ebola rapid** design of LASV **ELISA product** studies Filed patent on outbreak **Arevirumab-3** development **Bispecific Abs** diagnostics line **US FDA** 2013 2015 2016 2018 2017 2019 2020 2021 2023 **Launch of ReLASV** Zalgen -**NIAID** award Colorado **CEPI** award **Arevirumab-3 CEPI** award **Rapid Test – first** Maryland Multilineage **Diagnostics Patent awarded** LASV antigens LASV huMAb diagnostic test for diagnostics for **Development HQ** initiates supply to CEPI supply to Lassa to be CE **Center opens** LF **operations LASV** vaccine **CEPI LASV** Marked vaccine developers **Transfer of** developers diagnostic product **NIAID** award technology **CETR forLassa/Ebola Immunotherapeutics Transfer of FDA** development **EUA for ReEBOV**